These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29674291)

  • 1. Molecular modeling on porphyrin derivatives as β5 subunit inhibitor of 20S proteasome.
    Arba M; Nur-Hidayat A; Ruslin ; Yusuf M; Sumarlin ; Hertadi R; Wahyudi ST; Surantaadmaja SI; Tjahjono DH
    Comput Biol Chem; 2018 Jun; 74():230-238. PubMed ID: 29674291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore-based virtual screening for identifying β5 subunit inhibitor of 20S proteasome.
    Arba M; Nur-Hidayat A; Surantaadmaja SI; Tjahjono DH
    Comput Biol Chem; 2018 Dec; 77():64-71. PubMed ID: 30243108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling of cationic porphyrin-anthraquinone hybrids as DNA topoisomerase IIβ inhibitors.
    Arba M; Ruslin ; Ihsan S; Tri Wahyudi S; Tjahjono DH
    Comput Biol Chem; 2017 Dec; 71():129-135. PubMed ID: 29153891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrostatic Map Of Proteasome α-Rings Encodes The Design of Allosteric Porphyrin-Based Inhibitors Able To Affect 20S Conformation By Cooperative Binding.
    Dato AD; Cunsolo A; Persico M; Santoro AM; D'Urso A; Milardi D; Purrello R; Stefanelli M; Paolesse R; Tundo GR; Sbardella D; Fattorusso C; Coletta M
    Sci Rep; 2017 Dec; 7(1):17098. PubMed ID: 29213119
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    El Yaagoubi OM; Ezzemani W; Oularbi L; Samaki H; Aboudkhil S
    J Biomol Struct Dyn; 2024 Aug; 42(12):6165-6173. PubMed ID: 37403265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the 20S Proteasome Activity by Porphyrin Derivatives Is Steered through Their Charge Distribution.
    Persico M; Santoro AM; D'Urso A; Milardi D; Purrello R; Cunsolo A; Gobbo M; Fattorusso R; Diana D; Stefanelli M; Tundo GR; Sbardella D; Coletta M; Fattorusso C
    Biomolecules; 2022 May; 12(6):. PubMed ID: 35740865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico study of porphyrin-anthraquinone hybrids as CDK2 inhibitor.
    Arba M; Ihsan S; Ramadhan OA; Tjahjono DH
    Comput Biol Chem; 2017 Apr; 67():9-14. PubMed ID: 28024230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into Inhibitor Binding in the Eukaryotic Proteasome: Computations of the 20S CP.
    Hodošček M; Elghobashi-Meinhardt N
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30514002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding modes of cationic porphyrin-anthraquinone hybrids to DNA duplexes: in silico study.
    Arba M; Tjahjono DH
    J Biomol Struct Dyn; 2015; 33(3):657-65. PubMed ID: 24580066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular docking and dynamics simulations on the interaction of cationic porphyrin-anthraquinone hybrids with DNA G-quadruplexes.
    Arba M; Kartasasmita RE; Tjahjono DH
    J Biomol Struct Dyn; 2016; 34(2):427-38. PubMed ID: 25808513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cationic porphyrins are reversible proteasome inhibitors.
    Santoro AM; Lo Giudice MC; D'Urso A; Lauceri R; Purrello R; Milardi D
    J Am Chem Soc; 2012 Jun; 134(25):10451-7. PubMed ID: 22642538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
    Li A; Sun H; Du L; Wu X; Cao J; You Q; Li Y
    J Mol Model; 2014 Nov; 20(11):2515. PubMed ID: 25394401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of peptidomimetic boronates as proteasome inhibitors.
    Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
    Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits.
    Hovhannisyan AA; Pham TH; Bouvier D; Tan X; Touhar S; Mkryan GG; Dallakyan AM; El Amri C; Melikyan GS; Reboud-Ravaux M; Bouvier-Durand M
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5172-5178. PubMed ID: 29113763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
    Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A
    Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
    Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
    ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
    Marastoni M; Trapella C; Scotti A; Fantinati A; Ferretti V; Marzola E; Eleonora G; Gavioli R; Preti D
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):865-877. PubMed ID: 28657369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
    Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
    J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
    Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
    Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.